APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaccine Conjugate

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Vaccine Conjugate Industry Growth and Trends Forecast to 2032

Report ID 174044810126 December 2025104 pages

Choose your research edition.

Industry ResearchVaccine Conjugate Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Conjugate Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Vaccine Conjugate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Conjugate Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Conjugate Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Vaccine Conjugate market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vaccine Conjugate include Bharat Biotech, Beijing Minhai Biotechnology, Beijing Xiangrui Biological Products, Chengdu Olymvax Biopharmaceuticals, GSK, Pfizer, CanSinoBIO, Royal (Wuxi) Bio-Pharmaceutical and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Vaccine Conjugate market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Vaccine Conjugate market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Vaccine Conjugate market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Vaccine Conjugate.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Vaccine Conjugate market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Vaccine Conjugate Market by Company

Bharat Biotech

Beijing Minhai Biotechnology

Beijing Xiangrui Biological Products

Chengdu Olymvax Biopharmaceuticals

GSK

Pfizer

CanSinoBIO

Royal (Wuxi) Bio-Pharmaceutical

Merck

Sanofi

Walvax Biotechnology

Zhifei Biologic

Vaccine Conjugate Segment by Type

Hib Vaccine

Pneumococcal Vaccine

Meningococcal Vaccine

Others

Vaccine Conjugate Segment by Application

Children

Adult

Vaccine Conjugate Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Conjugate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine Conjugate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Conjugate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vaccine Conjugate manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Vaccine Conjugate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Hib Vaccine Table 2. Major Company of Pneumococcal Vaccine Table 3. Major Company of Meningococcal Vaccine Table 4. Major Company of Others Table 5. Global Vaccine Conjugate Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Vaccine Conjugate Sales by Type (2021-2026) & (K Units) Table 7. Global Vaccine Conjugate Sales Market Share in Volume by Type (2021-2026) Table 8. Global Vaccine Conjugate Sales by Type (2021-2026) & (US$ Million) Table 9. Global Vaccine Conjugate Sales Market Share in Value by Type (2021-2026) Table 10. Global Vaccine Conjugate Price by Type (2021-2026) & (US$/Unit) Table 11. Global Vaccine Conjugate Sales by Type (2027-2032) & (K Units) Table 12. Global Vaccine Conjugate Sales Market Share in Volume by Type (2027-2032) Table 13. Global Vaccine Conjugate Sales by Type (2027-2032) & (US$ Million) Table 14. Global Vaccine Conjugate Sales Market Share in Value by Type (2027-2032) Table 15. Global Vaccine Conjugate Price by Type (2027-2032) & (US$/Unit) Table 16. North America Vaccine Conjugate Sales by Type (2021-2026) & (K Units) Table 17. North America Vaccine Conjugate Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Vaccine Conjugate Sales by Type (2021-2026) & (K Units) Table 19. Europe Vaccine Conjugate Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Vaccine Conjugate Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Vaccine Conjugate Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Vaccine Conjugate Sales by Type (2021-2026) & (K Units) Table 23. Latin America Vaccine Conjugate Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Vaccine Conjugate Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Vaccine Conjugate Sales by Type (2021-2026) & (US$ Million) Table 26. Vaccine Conjugate Industry Trends Table 27. Vaccine Conjugate Industry Drivers Table 28. Vaccine Conjugate Industry Opportunities and Challenges Table 29. Vaccine Conjugate Industry Restraints Table 30. Global Vaccine Conjugate Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Vaccine Conjugate Revenue Market Share by Company (2021-2026) Table 32. Global Vaccine Conjugate Sales by Company (2021-2026) & (K Units) Table 33. Global Vaccine Conjugate Sales Share by Company (2021-2026) Table 34. Global Vaccine Conjugate Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Vaccine Conjugate Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Vaccine Conjugate Major Company Production Sites and Headquarters Table 37. Global Vaccine Conjugate Company, Product Type & Application Table 38. Global Vaccine Conjugate Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Vaccine Conjugate by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Vaccine Conjugate Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Vaccine Conjugate Sales by Region (2021-2026) & (K Units) Table 43. Global Vaccine Conjugate Sales Market Share in Volume by Region (2021-2026) Table 44. Global Vaccine Conjugate Sales by Region (2021-2026) & (US$ Million) Table 45. Global Vaccine Conjugate Sales Market Share in Value by Region (2021-2026) Table 46. Global Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Vaccine Conjugate Sales by Region (2027-2032) & (K Units) Table 48. Global Vaccine Conjugate Sales Market Share in Volume by Region (2027-2032) Table 49. Global Vaccine Conjugate Sales by Region (2027-2032) & (US$ Million) Table 50. Global Vaccine Conjugate Sales Market Share in Value by Region (2027-2032) Table 51. Global Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Vaccine Conjugate Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Vaccine Conjugate Sales by Application (2021-2026) & (K Units) Table 54. Global Vaccine Conjugate Sales Market Share in Volume by Application (2021-2026) Table 55. Global Vaccine Conjugate Sales by Application (2021-2026) & (US$ Million) Table 56. Global Vaccine Conjugate Sales Market Share in Value by Application (2021-2026) Table 57. Global Vaccine Conjugate Price by Application (2021-2026) & (US$/Unit) Table 58. Global Vaccine Conjugate Sales by Application (2027-2032) & (K Units) Table 59. Global Vaccine Conjugate Sales Market Share in Volume by Application (2027-2032) Table 60. Global Vaccine Conjugate Sales by Application (2027-2032) & (US$ Million) Table 61. Global Vaccine Conjugate Sales Market Share in Value by Application (2027-2032) Table 62. Global Vaccine Conjugate Price by Application (2027-2032) & (US$/Unit) Table 63. North America Vaccine Conjugate Sales by Application (2021-2026) & (K Units) Table 64. North America Vaccine Conjugate Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Vaccine Conjugate Sales by Application (2021-2026) & (K Units) Table 66. Europe Vaccine Conjugate Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Vaccine Conjugate Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Vaccine Conjugate Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Vaccine Conjugate Sales by Application (2021-2026) & (K Units) Table 70. Latin America Vaccine Conjugate Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Vaccine Conjugate Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Vaccine Conjugate Sales by Application (2021-2026) & (US$ Million) Table 73. Bharat Biotech Company Information Table 74. Bharat Biotech Business Overview Table 75. Bharat Biotech Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Bharat Biotech Vaccine Conjugate Product Portfolio Table 77. Bharat Biotech Recent Development Table 78. Beijing Minhai Biotechnology Company Information Table 79. Beijing Minhai Biotechnology Business Overview Table 80. Beijing Minhai Biotechnology Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolio Table 82. Beijing Minhai Biotechnology Recent Development Table 83. Beijing Xiangrui Biological Products Company Information Table 84. Beijing Xiangrui Biological Products Business Overview Table 85. Beijing Xiangrui Biological Products Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolio Table 87. Beijing Xiangrui Biological Products Recent Development Table 88. Chengdu Olymvax Biopharmaceuticals Company Information Table 89. Chengdu Olymvax Biopharmaceuticals Business Overview Table 90. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolio Table 92. Chengdu Olymvax Biopharmaceuticals Recent Development Table 93. GSK Company Information Table 94. GSK Business Overview Table 95. GSK Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. GSK Vaccine Conjugate Product Portfolio Table 97. GSK Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pfizer Vaccine Conjugate Product Portfolio Table 102. Pfizer Recent Development Table 103. CanSinoBIO Company Information Table 104. CanSinoBIO Business Overview Table 105. CanSinoBIO Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. CanSinoBIO Vaccine Conjugate Product Portfolio Table 107. CanSinoBIO Recent Development Table 108. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 109. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 110. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolio Table 112. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 113. Merck Company Information Table 114. Merck Business Overview Table 115. Merck Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Merck Vaccine Conjugate Product Portfolio Table 117. Merck Recent Development Table 118. Sanofi Company Information Table 119. Sanofi Business Overview Table 120. Sanofi Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Sanofi Vaccine Conjugate Product Portfolio Table 122. Sanofi Recent Development Table 123. Walvax Biotechnology Company Information Table 124. Walvax Biotechnology Business Overview Table 125. Walvax Biotechnology Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Walvax Biotechnology Vaccine Conjugate Product Portfolio Table 127. Walvax Biotechnology Recent Development Table 128. Zhifei Biologic Company Information Table 129. Zhifei Biologic Business Overview Table 130. Zhifei Biologic Vaccine Conjugate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Zhifei Biologic Vaccine Conjugate Product Portfolio Table 132. Zhifei Biologic Recent Development Table 133. North America Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 134. North America Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 135. North America Vaccine Conjugate Sales Market Share by Country (2021-2026) Table 136. North America Vaccine Conjugate Sales Forecast by Country (2027-2032) & (K Units) Table 137. North America Vaccine Conjugate Sales Market Share Forecast by Country (2027-2032) Table 138. North America Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Vaccine Conjugate Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Vaccine Conjugate Market Share by Country (2021-2026) Table 141. North America Vaccine Conjugate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Vaccine Conjugate Market Share Forecast by Country (2027-2032) Table 143. Europe Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 144. Europe Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 145. Europe Vaccine Conjugate Sales Market Share by Country (2021-2026) Table 146. Europe Vaccine Conjugate Sales Forecast by Country (2027-2032) & (K Units) Table 147. Europe Vaccine Conjugate Sales Market Share Forecast by Country (2027-2032) Table 148. Europe Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Europe Vaccine Conjugate Market Size by Country (2021-2026) & (US$ Million) Table 150. Europe Vaccine Conjugate Market Share by Country (2021-2026) Table 151. Europe Vaccine Conjugate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Europe Vaccine Conjugate Market Share Forecast by Country (2027-2032) Table 153. Asia-Pacific Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 154. Asia-Pacific Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 155. Asia-Pacific Vaccine Conjugate Sales Market Share by Country (2021-2026) Table 156. Asia-Pacific Vaccine Conjugate Sales Forecast by Country (2027-2032) & (K Units) Table 157. Asia-Pacific Vaccine Conjugate Sales Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Vaccine Conjugate Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Vaccine Conjugate Market Share by Country (2021-2026) Table 161. Asia-Pacific Vaccine Conjugate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Vaccine Conjugate Market Share Forecast by Country (2027-2032) Table 163. Latin America Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 164. Latin America Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 165. Latin America Vaccine Conjugate Sales Market Share by Country (2021-2026) Table 166. Latin America Vaccine Conjugate Sales Forecast by Country (2027-2032) & (K Units) Table 167. Latin America Vaccine Conjugate Sales Market Share Forecast by Country (2027-2032) Table 168. Latin America Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Latin America Vaccine Conjugate Market Size by Country (2021-2026) & (US$ Million) Table 170. Latin America Vaccine Conjugate Market Share by Country (2021-2026) Table 171. Latin America Vaccine Conjugate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Latin America Vaccine Conjugate Market Share Forecast by Country (2027-2032) Table 173. Middle East and Africa Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 174. Middle East and Africa Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 175. Middle East and Africa Vaccine Conjugate Sales Market Share by Country (2021-2026) Table 176. Middle East and Africa Vaccine Conjugate Sales Forecast by Country (2027-2032) & (K Units) Table 177. Middle East and Africa Vaccine Conjugate Sales Market Share Forecast by Country (2027-2032) Table 178. Middle East and Africa Vaccine Conjugate Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Middle East and Africa Vaccine Conjugate Market Size by Country (2021-2026) & (US$ Million) Table 180. Middle East and Africa Vaccine Conjugate Market Share by Country (2021-2026) Table 181. Middle East and Africa Vaccine Conjugate Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Middle East and Africa Vaccine Conjugate Market Share Forecast by Country (2027-2032) Table 183. Key Raw Materials Table 184. Raw Materials Key Suppliers Table 185. Vaccine Conjugate Distributors List Table 186. Vaccine Conjugate Customers List Table 187. Research Programs/Design for This Report Table 188. Authors List of This Report Table 189. Secondary Sources Table 190. Primary Sources List of Figures Figure 1. Vaccine Conjugate Image Figure 2. Global Vaccine Conjugate Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Conjugate Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaccine Conjugate Sales (2021-2032) & (K Units) Figure 5. Hib Vaccine Image Figure 6. Global Hib Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Pneumococcal Vaccine Image Figure 8. Global Pneumococcal Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Meningococcal Vaccine Image Figure 10. Global Meningococcal Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Vaccine Conjugate Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Vaccine Conjugate Market Share by Type 2025 VS 2032 Figure 15. North America Vaccine Conjugate Sales Market Share in Volume by Type in 2025 Figure 16. North America Vaccine Conjugate Sales Market Share in Value by Type in 2025 Figure 17. Europe Vaccine Conjugate Sales Market Share in Volume by Type in 2025 Figure 18. Europe Vaccine Conjugate Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Vaccine Conjugate Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Vaccine Conjugate Sales Market Share in Value by Type in 2025 Figure 21. Latin America Vaccine Conjugate Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Vaccine Conjugate Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Vaccine Conjugate Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Vaccine Conjugate Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Vaccine Conjugate Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Children Image Figure 28. Global Children Sales YoY Growth (2021-2032) & (K Units) Figure 29. Adult Image Figure 30. Global Adult Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Vaccine Conjugate Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Vaccine Conjugate Market Share by Application 2025 VS 2032 Figure 33. North America Vaccine Conjugate Sales Market Share in Volume by Application in 2025 Figure 34. North America Vaccine Conjugate Sales Market Share in Value by Application in 2025 Figure 35. Europe Vaccine Conjugate Sales Market Share in Volume by Application in 2025 Figure 36. Europe Vaccine Conjugate Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Vaccine Conjugate Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Vaccine Conjugate Sales Market Share in Value by Application in 2025 Figure 39. Latin America Vaccine Conjugate Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Vaccine Conjugate Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Vaccine Conjugate Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Vaccine Conjugate Sales Market Share in Value by Application in 2025 Figure 43. North America Vaccine Conjugate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Vaccine Conjugate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Vaccine Conjugate Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Vaccine Conjugate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Vaccine Conjugate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Vaccine Conjugate Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Vaccine Conjugate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Vaccine Conjugate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Vaccine Conjugate Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Vaccine Conjugate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Vaccine Conjugate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Vaccine Conjugate Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Vaccine Conjugate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Vaccine Conjugate Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Vaccine Conjugate Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Vaccine Conjugate Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Vaccine Conjugate Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Hib Vaccine
  • Pneumococcal Vaccine
  • Meningococcal Vaccine
  • Others
Applications
  • Children
  • Adult
Companies covered
  • Bharat Biotech
  • Beijing Minhai Biotechnology
  • Beijing Xiangrui Biological Products
  • Chengdu Olymvax Biopharmaceuticals
  • GSK
  • Pfizer
  • CanSinoBIO
  • Royal (Wuxi) Bio-Pharmaceutical
  • Merck
  • Sanofi
  • Walvax Biotechnology
  • Zhifei Biologic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vaccine Conjugate Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vaccine Conjugate Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Vaccine Conjugate Market by Type
  6. 1.3.1 Hib Vaccine
  7. 1.3.2 Pneumococcal Vaccine
  8. 1.3.3 Meningococcal Vaccine
  9. 1.3.4 Others
  10. 1.4 Global Vaccine Conjugate Market Size by Type
  11. 1.4.1 Global Vaccine Conjugate Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Vaccine Conjugate Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Vaccine Conjugate Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Vaccine Conjugate Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Vaccine Conjugate Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Vaccine Conjugate Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Vaccine Conjugate Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Vaccine Conjugate Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Vaccine Conjugate Industry Trends
  2. 2.2 Vaccine Conjugate Industry Drivers
  3. 2.3 Vaccine Conjugate Industry Opportunities and Challenges
  4. 2.4 Vaccine Conjugate Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Vaccine Conjugate Revenue (2021-2026)
  2. 3.2 Global Top Players by Vaccine Conjugate Sales (2021-2026)
  3. 3.3 Global Top Players by Vaccine Conjugate Price (2021-2026)
  4. 3.4 Global Vaccine Conjugate Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vaccine Conjugate Major Company Production Sites & Headquarters
  6. 3.6 Global Vaccine Conjugate Company, Product Type & Application
  7. 3.7 Global Vaccine Conjugate Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vaccine Conjugate Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vaccine Conjugate Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vaccine Conjugate Tier 1, Tier 2, and Tier 3
4 Vaccine Conjugate Regional Status and Outlook
  1. 4.1 Global Vaccine Conjugate Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Vaccine Conjugate Historic Market Size by Region
  3. 4.2.1 Global Vaccine Conjugate Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Vaccine Conjugate Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Vaccine Conjugate Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Vaccine Conjugate Forecasted Market Size by Region
  7. 4.3.1 Global Vaccine Conjugate Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Vaccine Conjugate Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Vaccine Conjugate Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Vaccine Conjugate by Application
  1. 5.1 Vaccine Conjugate Market by Application
  2. 5.1.1 Children
  3. 5.1.2 Adult
  4. 5.2 Global Vaccine Conjugate Market Size by Application
  5. 5.2.1 Global Vaccine Conjugate Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Vaccine Conjugate Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Vaccine Conjugate Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Vaccine Conjugate Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Vaccine Conjugate Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Vaccine Conjugate Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Vaccine Conjugate Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Vaccine Conjugate Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bharat Biotech
  2. 6.1.1 Bharat Biotech Company Information
  3. 6.1.2 Bharat Biotech Business Overview
  4. 6.1.3 Bharat Biotech Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bharat Biotech Vaccine Conjugate Product Portfolio
  6. 6.1.5 Bharat Biotech Recent Developments
  7. 6.2 Beijing Minhai Biotechnology
  8. 6.2.1 Beijing Minhai Biotechnology Company Information
  9. 6.2.2 Beijing Minhai Biotechnology Business Overview
  10. 6.2.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolio
  12. 6.2.5 Beijing Minhai Biotechnology Recent Developments
  13. 6.3 Beijing Xiangrui Biological Products
  14. 6.3.1 Beijing Xiangrui Biological Products Company Information
  15. 6.3.2 Beijing Xiangrui Biological Products Business Overview
  16. 6.3.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolio
  18. 6.3.5 Beijing Xiangrui Biological Products Recent Developments
  19. 6.4 Chengdu Olymvax Biopharmaceuticals
  20. 6.4.1 Chengdu Olymvax Biopharmaceuticals Company Information
  21. 6.4.2 Chengdu Olymvax Biopharmaceuticals Business Overview
  22. 6.4.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolio
  24. 6.4.5 Chengdu Olymvax Biopharmaceuticals Recent Developments
  25. 6.5 GSK
  26. 6.5.1 GSK Company Information
  27. 6.5.2 GSK Business Overview
  28. 6.5.3 GSK Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 GSK Vaccine Conjugate Product Portfolio
  30. 6.5.5 GSK Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Vaccine Conjugate Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 CanSinoBIO
  38. 6.7.1 CanSinoBIO Company Information
  39. 6.7.2 CanSinoBIO Business Overview
  40. 6.7.3 CanSinoBIO Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 CanSinoBIO Vaccine Conjugate Product Portfolio
  42. 6.7.5 CanSinoBIO Recent Developments
  43. 6.8 Royal (Wuxi) Bio-Pharmaceutical
  44. 6.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  45. 6.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  46. 6.8.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolio
  48. 6.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  49. 6.9 Merck
  50. 6.9.1 Merck Company Information
  51. 6.9.2 Merck Business Overview
  52. 6.9.3 Merck Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Merck Vaccine Conjugate Product Portfolio
  54. 6.9.5 Merck Recent Developments
  55. 6.10 Sanofi
  56. 6.10.1 Sanofi Company Information
  57. 6.10.2 Sanofi Business Overview
  58. 6.10.3 Sanofi Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Sanofi Vaccine Conjugate Product Portfolio
  60. 6.10.5 Sanofi Recent Developments
  61. 6.11 Walvax Biotechnology
  62. 6.11.1 Walvax Biotechnology Company Information
  63. 6.11.2 Walvax Biotechnology Business Overview
  64. 6.11.3 Walvax Biotechnology Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Walvax Biotechnology Vaccine Conjugate Product Portfolio
  66. 6.11.5 Walvax Biotechnology Recent Developments
  67. 6.12 Zhifei Biologic
  68. 6.12.1 Zhifei Biologic Company Information
  69. 6.12.2 Zhifei Biologic Business Overview
  70. 6.12.3 Zhifei Biologic Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Zhifei Biologic Vaccine Conjugate Product Portfolio
  72. 6.12.5 Zhifei Biologic Recent Developments
7 North America by Country
  1. 7.1 North America Vaccine Conjugate Sales by Country
  2. 7.1.1 North America Vaccine Conjugate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Vaccine Conjugate Sales by Country (2021-2026)
  4. 7.1.3 North America Vaccine Conjugate Sales Forecast by Country (2027-2032)
  5. 7.2 North America Vaccine Conjugate Market Size by Country
  6. 7.2.1 North America Vaccine Conjugate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Vaccine Conjugate Market Size by Country (2021-2026)
  8. 7.2.3 North America Vaccine Conjugate Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Vaccine Conjugate Sales by Country
  2. 8.1.1 Europe Vaccine Conjugate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Vaccine Conjugate Sales by Country (2021-2026)
  4. 8.1.3 Europe Vaccine Conjugate Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Vaccine Conjugate Market Size by Country
  6. 8.2.1 Europe Vaccine Conjugate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Vaccine Conjugate Market Size by Country (2021-2026)
  8. 8.2.3 Europe Vaccine Conjugate Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Vaccine Conjugate Sales by Country
  2. 9.1.1 Asia-Pacific Vaccine Conjugate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Vaccine Conjugate Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Vaccine Conjugate Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Vaccine Conjugate Market Size by Country
  6. 9.2.1 Asia-Pacific Vaccine Conjugate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Vaccine Conjugate Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Vaccine Conjugate Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Vaccine Conjugate Sales by Country
  2. 10.1.1 South America Vaccine Conjugate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Vaccine Conjugate Sales by Country (2021-2026)
  4. 10.1.3 South America Vaccine Conjugate Sales Forecast by Country (2027-2032)
  5. 10.2 South America Vaccine Conjugate Market Size by Country
  6. 10.2.1 South America Vaccine Conjugate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Vaccine Conjugate Market Size by Country (2021-2026)
  8. 10.2.3 South America Vaccine Conjugate Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Vaccine Conjugate Sales by Country
  2. 11.1.1 Middle East and Africa Vaccine Conjugate Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Vaccine Conjugate Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Vaccine Conjugate Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Vaccine Conjugate Market Size by Country
  6. 11.2.1 Middle East and Africa Vaccine Conjugate Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Vaccine Conjugate Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Vaccine Conjugate Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Vaccine Conjugate Value Chain Analysis
  2. 12.1.1 Vaccine Conjugate Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Vaccine Conjugate Production Mode & Process
  7. 12.2 Vaccine Conjugate Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Vaccine Conjugate Distributors
  10. 12.2.3 Vaccine Conjugate Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst